Table 1.
Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups.
| Variable | Survival (n = 36) |
Death (n = 26) |
P-value |
|---|---|---|---|
| Demographics | |||
| Age, years | 67 (54–73) | 71 (58–76) | 0.199 |
| Male, n (%) | 18 (50.0%) | 11 (42.3%) | 0.549 |
| Chronic comorbidities, n (%) | |||
| Hypertension | 11 (30.6%) | 10 (38.5%) | 0.516 |
| Diabetes mellitus | 3 (8.3%) | 2 (7.7%) | 1.000 |
| Malignancy | 1 (2.8%) | 0 (0%) | 1.000 |
| CAD | 1 (2.8%) | 0 (0%) | 1.000 |
| COPD | 0 (0%) | 1 (3.9%) | 0.419 |
| Clinical manifestations, n (%) | |||
| Nausea | 12 (33.3%) | 7 (26.9%) | 0.589 |
| Vomiting | 10 (27.8%) | 9 (34.6%) | 0.564 |
| Celialgia | 4 (11.1%) | 2 (7.7%) | 0.653 |
| Diarrhea | 17 (47.2%) | 10 (38.5%) | 0.492 |
| Unintelligible speech | 1 (2.8%) | 3(11.5%) | 0.300 |
| Dizziness and headache | 18 (50.0%) | 6 (23.1%) | 0.032 |
| Cough | 9 (25.0%) | 4 (15.4%) | 0.359 |
| Sputum | 7 (19.4%) | 3 (11.5%) | 0.627 |
| Chest tightness | 3 (8.3%) | 3 (11.5%) | 0.689 |
| Rash | 6 (16.7%) | 1 (3.8%) | 0.222 |
| Lymphadenopathy | 13 (36.1%) | 7 (26.9%) | 0.445 |
| Bleeding spots on the skin | 7 (19.4%) | 9 (34.6%) | 0.178 |
| Laboratory parameters | |||
| WBC count, median (IQR), ×109/L |
2.5 (1.8–4.6) | 2.7 (1.7–3.7) | 0.898 |
| ANC count, median (IQR), ×109/L | 1.7 (1.0–2.9) | 2.1 (1.2–2.8) | 0.668 |
| ALC count, median (IQR), ×109/L | 0.7 (0.4–0.9) | 0.5 (0.3–0.6) | 0.042 |
| NLR, median (IQR) | 2.2 (1.5–6.1) | 3.3 (1.9–9.1) | 0.136 |
| RDW, median (IQR), % | 13.2 (12.8–13.5) | 13.6 (12.8–14.3) | 0.071 |
| PLT count, median (IQR), ×109/L | 44.5 (33.8–61.3) | 39.5 (29.0–58.5) | 0.480 |
| PLR, median (IQR) | 65.5 (39.3–146.0) | 89.6 (67.5–145.0) | 0.248 |
| PT, median (IQR), s | 12.0 (11.2–12.6) | 12.4 (11.7–13.0) | 0.123 |
| APTT, median (IQR), s | 41.4 (33.6–46.3) | 48.5 (37.6–61.1) | 0.009 |
| TT, median (IQR), s | 22.8 (21.1–27.7) | 26.9 (21.8–57.9) | 0.057 |
| D-dimer, median (IQR), mg/L | 3.8 (2.3–9.2) | 9.9 (3.4–22.6) | 0.018 |
| ALT, median (IQR), U/L | 69.6 (54.3–97.2) | 75.3 (50.5–90.5) | 0.881 |
| AST, median (IQR), U/L | 172.5 (93.4–312.9) | 222.0 (114.1–321.8) | 0.304 |
| ALB, median (IQR), g/L | 32.0 (28.7–35.7) | 31.7 (29.1–34.1) | 0.775 |
| TBIL, median (IQR), µmol/L | 11.0 (8.6–13.9) | 7.7 (5.8–11.5) | 0.066 |
| SCr, median (IQR), µmol/L | 72.5 (48.8–89.6) | 82 (67.5–123.6) | 0.090 |
| BUN, median (IQR), mmol/L | 5.2 (3.5–7.1) | 5.9 (4.8–10.6) | 0.061 |
| UA, median (IQR), µmol/L | 306 (236–347) | 342 (231–463) | 0.471 |
| IVIG usage | |||
| IVIG dosage, g | 95.0 (57.5–100.0) | 60.0 (40.0–100.0) | 0.066 |
| IVIG duration, d | 5 ± 2 | 4 ± 2 | 0.003 |
| Additional information | |||
| Time from onset to arriving in hospital, d | 7 ± 3 | 7 ± 2 | 0.317 |
| Time from onset to IVIG treatment, d | 9 ± 3 | 9 ± 3 | 0.677 |
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; RDW, red cell volume distribution width; PLT, platelet; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; SCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; IVIG, intravenous immunoglobulin; IQR, interquartile range.